

Prior to reconsideration, Applicants request that the Office enter the following amendments:

***IN THE SPECIFICATION***

At page 1, after the title and before the first full paragraph, please insert the heading  
**"STATEMENT REGARDING GOVERNMENT SPONSORED RESEARCH."**

( 2. At page 1, line 5, please delete the second full paragraph and insert the following heading and new paragraph: )

**CROSS REFERENCE TO RELATED APPLICATIONS**

This application is a continuation of U. S. serial No. 09/143,369 filed August 28, 1998, now U. S. patent No. 6,280,956, which is a continuation-in-part of U.S. serial No. 08/742,850, filed November 1, 1996, now U. S. patent No. 5,866,535, which in turn, claims priority to U.S. provisional Application No. 60/006,226, filed November 3, 1995.

***IN THE TITLE***

Please delete the original title of the invention and insert a new title that is descriptive of the claimed invention as follows:

**"AN ANTIBODY TO BLADDER CANCER NUCLEAR  
MATRIX PROTEIN AND ITS USE"**

***IN THE CLAIMS***

In accordance with 37 C.F.R. § 1.121, please substitute claims 1 and 10 with the following rewritten version of the same claims, as amended. The changes are shown explicitly in the attached "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Claim 1. (currently amended): An isolated or purified antibody that specifically binds to a nuclear matrix protein or an antigenic fragment thereof, wherein said nuclear matrix protein is present in cancerous bladder cells but absent in normal bladder cells, and wherein the nuclear matrix protein is BLCA-6 having a molecular weight of about 31 kD and a pI of about 8.00.

Claims 2-6 (withdrawn).

Claim 7 (cancelled).

Claims 8-9 (withdrawn).